HSPG2 and acute myeloid leukemia: As highlighted by the comparison of ROC curves (Fig. 3d), HSPG2 expression alone is enough to obtain high predictive accuracy for 2-year survival in whole-cohort AML (HSPG2 expression-AUC = 0.663, 95% CI: 0.572–0.754, P = 0.002), as compared with the predictive capacity of BM blasts (BM blasts-AUC = 0.613, 95% CI: 0.516–0.710, P = 0.034).